![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy by Race or Geographic Region in HCV Genotype 1-Infected Patients Treated With ABT-450/Ritonavir/Ombitasvir
and Dasabuvir With or Without Ribavirin
|
|
|
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
John Vierling1, Massimo Puoti 2, David Bernstein3, Naoky Tsai4, Ola Weiland5, Manuel Romero-Gómez6, Florin Alexandru Caruntu7, Jean-Francois DuFour8, Filipe Calinas9, Lois Larsen10, Fernando Tatsch10,
Pietro Andreone11
1Baylor College of Medicine and Advanced Liver Therapies, Houston, Texas, United States; 2AO Ospedale Niguarda Ca Granda, Milan, Italy; 3North Shore University Hospital, Manhasset, New York, United States; 4Queen's Medical Center, University of Hawaii, Honolulu, Hawaii, United States;
5Karolinska University Hospital Huddinge, Karolinska Insti tutet, Stockholm, Sweden; 6Hospital Universitario Nuestra Señora de Valme, Seville, Spain; 7Nati onal Insti tute for Infecti ous Diseases "Matei Bals," Bucharest, Romania; 8University Clinic for Visceral Surgery and Medicine, Bern, Switzerland;
9Centro Hospitalar Lisboa Central, EPE - Hosp. St. Antonio dos Capuchos, Lisbon, Portugal; 10AbbVie Inc., North Chicago, Illinois, United States; 11Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
![AASLD1.gif](../images/111414/111414-3/AASLD1.gif)
![AASLD2.gif](../images/111414/111414-3/AASLD2.gif)
![AASLD3.gif](../images/111414/111414-3/AASLD3.gif)
![AASLD4.gif](../images/111414/111414-3/AASLD4.gif)
![AASLD5.gif](../images/111414/111414-3/AASLD5.gif)
![AASLD6.gif](../images/111414/111414-3/AASLD6.gif)
![AASLD7.gif](../images/111414/111414-3/AASLD7.gif)
![AASLD8.gif](../images/111414/111414-3/AASLD8.gif)
![AASLD9.gif](../images/111414/111414-3/AASLD9.gif)
![AASLD10.gif](../images/111414/111414-3/AASLD10.gif)
![AASLD11.gif](../images/111414/111414-3/AASLD11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|